Podium Presentation in Room 2 on Wednesday at 9:20 (Chair: Melanie Odenkirk)
Authors: Kim Ekroos (1), Gerhard Liebisch (2), Michal Holčapek (3), Robert Ahrends (4), Harald Köfeler (5), Xianlin Han (6) and Markus Wenk (7)
INTRODUCTION: Lipid metabolism is tightly regulated to maintain homeostasis. Loss of control can result in unwanted cascades of biological events triggering deleterious pathophysiological conditions. The evolution of lipidomics technologies is set to tackle this problem, driven by high expectation in its ability to afford new opportunities for studying lipids in health and disease, and put forward new biomarker candidates. However, many studies differ vastly in methodologies, workflows and data presentation and do not report absolute lipid concentrations, hampering a successful transition of lipidomics into the clinical landscape.
OBJECTIVES: Our prime objective was to identify a solution aiming to harmonize and standardize the field of lipidomics.
METHODS: We performed exhaustive discussions, presentations and workshops through-out the lipidomics community to identify the current gaps and needs.
RESULTS: We have established the International Lipidomics Society (ILS) flagship, fostering international community-wide coordination and communication for the creation of lipidomics specific guidelines for good scientific practice and future development. A central focus lies, among others, in the engagements of working groups actively developing lipidomics standards guidelines, reference materials, clinical lipidomics, and a close crosstalk to lipid biology and medicine.
CONCLUSIONS: ILS is the point of contact for lipidomics research, development and commercialization, and actively guiding the developments closer towards the clinical arena.
|Planning to mention or discuss specific products or technology of the company(ies) listed above:||